| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,410,700 | -2,257,890 |
| Change in right-of-use assets | 17,994 | 17,994 |
| Impairment of right-of-use assets | 108,759 | 108,759 |
| Prepaid expenses | -47,144 | -1,160 |
| Lease liabilities | -4,925 | -4,925 |
| Deposits | -49,130 | -49,129 |
| Accounts payable | 515,662 | 339,199 |
| Accrued expenses | 158,276 | 163,396 |
| Other liabilities | 789,460 | 709,665 |
| Net cash used in operating activities | -1,729,201 | -873,513 |
| Cash acquired in acquisition of imgx | 336,427 | - |
| Net cash provided by investing activities | 336,427 | - |
| Proceeds from issuance of common stock, prefunded warrants and warrants, net | 3,025,000 | - |
| Proceeds from line of credit | 700,000 | 700,000 |
| Net cash provided by financing activities | 3,725,000 | 700,000 |
| Net (decrease) in cash, cash equivalents and restricted cash | 2,332,226 | -173,513 |
| Cash and cash equivalents at beginning of period | 184,992 | - |
| Cash and cash equivalents at end of period | 2,517,218 | - |
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)